@imperialNHLI Prof of Interstitial lung disease | @asthmalunguk Prof of Respiratory Research | Director NIHR CRF @RBandH and #IPF doctor. Working to #cureIPF
London, England
Joined October 2010
- Tweets614
- Following577
- Followers979
- Likes1.3K
Phil Molyneaux retweeted
Delighted that our study mapping the #proteome in #SLE is now published in @JCI_insight . Great work from the team especially grad student Geoffrey Leung
insight.jci.org/articles/vie…
Phil Molyneaux retweeted
Join Strados Labs at #ATS2026 for an Innovation Hub session presented by @drphilmol on cough in respiratory diseases—spanning clinical trials & patient care.
May 17 | 11:55–12:15 | Innovation Hub 3
Add to calendar: addevent.com/event/6j9qqls7b…
#respiratoryresearch #clinicaltrials
Join the European Respiratory Society (ERS) this March for the Academy of interstitial lung diseases!
This ERS course will provide updates on diagnostic procedures, specific diseases and treatment! Learn more and register:
ersnet.org/events/academy-of…
Phil Molyneaux retweeted
📊 Research Summary: Higher doses of nalbuphine ER led to greater cough reduction in idiopathic pulmonary fibrosis; adverse events were consistent with those expected for opioid-class medications.
ja.ma/3ZbF1OZ
ALT JAMA Research Summary: Oral Nalbuphine in Idiopathic Pulmonary Fibrosis-Associated Cough. Nalbuphine ER 27mg, 54mg, 108mg, and Placebo show cough reduction rates of 47.9%, 53.4%, 60.2%, and 16.9% respectively.
Phil Molyneaux retweeted
Trevi is pleased to announce the publication of data from the Phase 2b IPF chronic cough trial of nalbuphine ER in the Journal of the American Medical Association (JAMA).
Read the press release and access the publication here: ow.ly/BORg50Y1jS3
@drphilmol @JAMA_current
Phil Molyneaux retweeted
Nice to see a joint call for papers from @LancetRespirMed and @ThoraxBMJ for the @BTSrespiratory winter meeting
Deadline 30th June. Come on brilliant bronchiectasis and airways colleagues- lets get some great papers in the queue for this 😀
thelancet.com/journals/lanre…
Phil Molyneaux retweeted
We have a one year clinical fellow post (maternity cover) available. Study looking at human viral challenge in bronchiectasis. Would suit IMT or specialist respiratory trainee. Details: imperial.ac.uk/jobs/search-j… Grateful for retweets. Please DM/email if interested.
Phil Molyneaux retweeted
Congratulations to @RBandH for recruiting two participants to the CHORUS Trial in December 🥳
Phil Molyneaux retweeted
Ahead of Respiratory Conference on 13 March, we’re featuring some of the fantastic respiratory medical experts who’ll speak at the event. Speakers will include @drphilmol in session one covering ILD & @RichardJHewitt focusing on ILAs in session 3. Book at: rcp.sg/respc
Phil Molyneaux retweeted
If you missed our onsite event in March, why not register for the virtual academy of interstitial lung diseases?
This course will cover ILD diagnosis, plus current, novel and future therapies and more!
Register now: bit.ly/4izseNx
Phil Molyneaux retweeted
The weekly cancer MDT meeting can cause treatment delays, result in poor quality decisions, and waste clinicians’ time, say @tomroques and colleagues.
It’s time for a fresh approach
bmj.com/content/391/bmj.r224…
Phil Molyneaux retweeted
In the IMPALA-2 phase 3 trial, the inhaled recombinant human GM-CSF molgramostim improved pulmonary gas transfer in patients with autoimmune pulmonary alveolar proteinosis. Full trial results and Research Summary: nej.md/476PdNU
ALT The New England Journal of Medicine Inhaled Molgramostim in Autoimmune Pulmonary Alveolar Proteinosis A Research Summary based on Trapnell BC et al. | 10.1056/NEJMoa2410542 | Published on August 21, 2025 Visual representations of the patients in the trial and the treatments they were assigned. Read the full Research Summary at NEJM.org.
Phil Molyneaux retweeted
📢 Save the date!
Join us on 10 Sept 2025 for an #ILDIN webinar with @drphilmol
“From Calm to Crisis: ILD Acute Exacerbations”
➡️ For ILD-IN members. Registration info coming soon via email.
#ILD #ERS #LungHealth
It is a great privilege to have @drphilmol as guest speaker for the first in our exciting webinar series on 10th September. Access details have been emailed to ILD-IN members. Don't miss this fantastic opportunity to hear Prof Molyneaux share his expertise in ILD.
Phil Molyneaux retweeted
Editorial: The Future of academic respiratory medicine - near crisis point. thorax.bmj.com/content/80/9/…
Phil Molyneaux retweeted
Huge congratulations to the team @RoyalDevonNHS for recruiting the first participant into the Chorus trial! 🥇🎉
Phil Molyneaux retweeted
The #ILD clinical and research team in Exeter 🇬🇧 is excited to have our site ready to recruit patients with fibrotic hypersensitivity pneumonitis into the @ChorusTrial 🫁 #Teamwork @ActionPFcharity
#FibroticHP #RCT #Steroids vs #Placebo 💊💊
Great news! The CHORUS Trial is now open to recruitment, congratulations to @PilarRiveraOrt1 and her team for being the first site to open. @RoyalDevonNHS Excited to get started 🎉📷 @ActionPFcharity
Phil Molyneaux retweeted
👇Charities make a truly colossal contribution to medical research. Thanks to our donors and supporters, charities like us @aluk_research, are vital to driving forward positive health changes. Important data collation, analysis and presentation from the @AMRC 👏
Our annual infographic showcases the collective impact of our members and their incredible support for UK medical research.
@AMRC charities invest in universities and the NHS, as well as supporting the R&D workforce from the earliest stages of their careers: shorturl.at/hocmR #CharityImpact
